Payload

Fairytale ending? Mythic flags new approach to improving ADC performance

04-Jan-2022 By Jane Byrne

December 2021 saw the launch of a new US based biotech, Mythic Therapeutics, with an oversubscribed Series B financing round of US$103m.

Novasep secures manufacturing deal with US biotech for ADC drug candidate

06-Jul-2021 By Jane Byrne

Novasep has signed a manufacturing services agreement with Exelixis, an oncology-focused US biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC).

New targets and DNA modifying payload addition set to enhance ADC work at Iksuda

24-Jun-2021 By Jane Byrne

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

BMS bets on ADC potential with $3.1bn Eisai partnership

22-Jun-2021 By Ben Hargreaves

BMS buys into co-development of Eisai’s first ADC targeting advanced solid tumors.

ADC developer, Iksuda Therapeutics, closes $47m financing round

07-Jun-2021 By Jane Byrne

UK-based biotechnology company, Iksuda Therapeutics, has completed a US$47m (£34m) financing round, which was led by Mirae Asset financial group and included a strategic investment from Korean biopharma player, Celltrion.

Can Hootsuite like interface tackle data management challenges in ADC manufacturing?

20-May-2021 By Jane Byrne

Data management in antibody drug conjugate (ADC) manufacturing is challenging says ADC/Labs, which is trying to help scientists in the field get around such obstacles.